This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:physicians:concerns [02.09.2019] – [Numerical improvements update] sallieq | home:physicians:concerns [06.07.2019] – [Recorded success rates assessed 2013] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Physicians' | ====== Physicians' | ||
+ | |||
+ | < | ||
Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home: | Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home: | ||
Line 5: | Line 7: | ||
===== Concerns about lack of clinical evidence ===== | ===== Concerns about lack of clinical evidence ===== | ||
- | - **" | + | - **" |
* a [[home: | * a [[home: | ||
* a [[home: | * a [[home: | ||
Line 16: | Line 18: | ||
For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: | For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: | ||
* evidence for the efficacy of MP versus other available treatment options(({{pubmed> | * evidence for the efficacy of MP versus other available treatment options(({{pubmed> | ||
+ | * 2013 material on patient response, see section below | ||
* patients' | * patients' | ||
* additional benefits of Olmesartan [[https:// | * additional benefits of Olmesartan [[https:// | ||
Line 24: | Line 27: | ||
< | < | ||
- | ===== Numerical improvements update | + | ===== Recorded results assessed 2013 |
< | < | ||
- | See [[home: | + | Resulting in [[home: |
+ | |||
+ | < | ||
+ | |||
+ | I was intending to compare this to the 10% success rate I found done on the use of prednisone to treat Sarcoidosis. That double blind report shows that 10% treated with prednisone achieve remission. (BTW remission in Sarcoidosis as far as I can find out is measured rather subjectively) | ||
+ | |||
+ | (This) is what I found: | ||
+ | |||
+ | Sarcoidosis: | ||
+ | |||
+ | Chronic Fatigue Syndrome: 183 members; 110 success; 30 no success; 43 unsure | ||
+ | |||
+ | Lyme Disease: 169 members; 113 success; 23 no success; 33 unsure | ||
+ | |||
+ | Rheumatoid arthritis: 39 members; 27 success; 5 no success; 7 unsure | ||
+ | |||
+ | Fibromyalgia: | ||
+ | |||
+ | Other Th1 diseases: 184 members; 110 success; 30 no success 44 unsure | ||
+ | |||
+ | TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear. | ||
+ | |||
+ | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
+ | |||
+ | Sarcoidosis success 75.8% | ||
+ | |||
+ | Chronic Fatigue Syndrome success 60.1% | ||
+ | |||
+ | Lyme disease success 66.9% | ||
+ | |||
+ | Rheumatoid arthritis success 69.2% | ||
+ | |||
+ | Fibromyalgia success 64.2% </ | ||
===== Concerns about olmesartan (Benicar) ===== | ===== Concerns about olmesartan (Benicar) ===== | ||
Line 71: | Line 106: | ||
==== Read also ==== | ==== Read also ==== | ||
+ | |||
+ | [[http:// | ||
**Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.**\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases. | **Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.**\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases. | ||
Line 78: | Line 115: | ||
- | {{tag> | + | {{tag> |
+ | |||
+ | [[home: | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||